LGVN - צמיחת הכנסות ב-12 חודשים נגררים longeveron.com

לוגו גרפי של Longeveron Inc. (LGVN)

High binary risks for Longeveron Inc. (LGVN) due to its narrow specialization in cell technologies are partially offset by grants. The LTM sales growth YoY metric visualizes operational efficiency, where the -18.70 mark serves as the current indicator. Fundamental growth is driven by the success of the Lomecel-B drug and merger potential. Longeveron Inc. (LGVN) is strengthening its reputation as an innovator in regenerative medicine through the development of methods to combat biological aging.

LGVN (Longeveron Inc.) היסטוריית צמיחת מכירות משנה לשנה (TTM) מ-11.02.2024 עד 18.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור Longeveron Corporation (LGVN)

- מחיר ותחזית קונצנזוס למחירים:
ניתוח כל מדדי החברה:Longeveron Inc. - LGVN
פריט של המותג Longeveron Corp

This indicator determines the real resilience of the business to external shocks by analyzing revenue growth rates. The year-over-year dynamics of core revenue over a rolling 12-month period neutralize seasonality by comparing current income with the same window from the previous year. Growth in this value confirms the scaling of commercial success and the liquidity of the asset. For Longeveron Inc. (LGVN), this metric reflects the monetization of the unique drug Lomecel-B. High pricing power in the Alzheimer's therapy segment renders revenue inelastic.